-
1.发明申请Method for Recognizing Acute Generalized Inflammatory Conditions (Sirs), Sepsis, Sepsis-Like Conditions and Systemic Infections 审中-公开识别急性广泛性炎症病症（Sirs）的方法，败血症，脓毒症状况及全身感染公开(公告)号：US20080070235A1
公开(公告)日：2008-03-20
申请号：US10551874
申请日：2004-03-31
申请人： Stefan Russwurm , Konrad Reinhart , Hans-Peter Saluz , Eberhard Straube , Peter Zipfel , Hans-Peter Deigner
发明人： Stefan Russwurm , Konrad Reinhart , Hans-Peter Saluz , Eberhard Straube , Peter Zipfel , Hans-Peter Deigner
CPC分类号： C12Q1/6883 , B82Y5/00 , B82Y10/00 , C12Q1/6837 , C12Q2600/158 , Y10T436/143333
摘要： The present invention relates to a method for in vitro detection of SIRS, sepsis and/or sepsis-like conditions. This method renders the evaluation of the severity and/or the therapeutic progress of sepsis and severe infections, in particular sepsis-like systemic infections possible. Further, the present invention relates to the use of recombinantly or synthetically prepared nucleic acid sequences or peptide sequences derived therefrom as calibrator in sepsis assays and/or for the evaluation of the effect and the toxicity during screening of the active agents and/or the preparation of therapeutics for the prevention and treatment of SIRS, sepsis, sepsis-like systemic inflammatory conditions and sepsis-like systemic infections.
摘要翻译： 本发明涉及一种用于体外检测SIRS，败血症和/或脓毒病样条件的方法。 该方法可以评估败血症和严重感染的严重性和/或治疗进展，特别是脓毒症样全身感染。 此外，本发明涉及重组或合成制备的核酸序列或其衍生的肽序列作为脓毒症测定中的校准物和/或用于评估活性剂和/或制剂筛选过程中的作用和毒性的用途 用于预防和治疗SIRS，败血症，败血症样全身性炎症病症和败血症样全身感染的治疗剂。
-
2.发明申请公开(公告)号：US20060134685A1
公开(公告)日：2006-06-22
申请号：US11349387
申请日：2006-02-06
CPC分类号： C12Q1/6837
摘要： The application relates to the use of a nucleic acid and/or protein chip comprising probe nucleic acids and/or probe proteins, which are specific for cellular stress, inflammatory and immune reactions, associated with stress, inflammatory and immune reactions, induced during acute phase responses or any combination thereof and which are immobilised on a carrier for the diagnosis of sepsis or sepsis related syndrome.
摘要翻译： 本申请涉及包含探针核酸和/或探针蛋白的核酸和/或蛋白质芯片在与急性期诱导的应激，炎症和免疫反应相关的细胞应激，炎性和免疫反应特异性的应用 反应或其任何组合，并且其固定在用于诊断败血症或败血症相关综合征的载体上。
-
公开(公告)号：US20100184608A1
公开(公告)日：2010-07-22
申请号：US12529423
申请日：2008-02-28
CPC分类号： C12Q1/6876 , C12Q1/6837 , C12Q2600/158 , C12Q2600/166 , C12Q2545/101
摘要： The present invention relates to reference genes, primers, and probes for the normalization of gene expression analysis data from blood samples of a patient. The invention further relates to a method for the normalization of gene expression analysis data with the aid of reference genes, primers, or probes.
摘要翻译： 本发明涉及用于从患者的血液样品中归一化基因表达分析数据的参考基因，引物和探针。 本发明还涉及借助于参考基因，引物或探针使基因表达分析数据归一化的方法。
-
4.发明授权公开(公告)号：US08338099B2
公开(公告)日：2012-12-25
申请号：US12529423
申请日：2008-02-28
CPC分类号： C12Q1/6876 , C12Q1/6837 , C12Q2600/158 , C12Q2600/166 , C12Q2545/101
摘要： The present invention relates to reference genes, primers, and probes for the normalization of gene expression analysis data from blood samples of a patient. The invention further relates to a method for the normalization of gene expression analysis data with the aid of reference genes, primers, or probes.
摘要翻译： 本发明涉及用于从患者的血液样品中归一化基因表达分析数据的参考基因，引物和探针。 本发明还涉及借助于参考基因，引物或探针使基因表达分析数据归一化的方法。
-
5.发明授权Method for enriching and/or separating prokaryotic DNA using a protein that specifically bonds to unmethylated DNA containing CpG-motifs 失效使用特异性结合含有CpG基序的未甲基化DNA的蛋白质来富集和/或分离原核DNA的方法公开(公告)号：US08481262B2
公开(公告)日：2013-07-09
申请号：US10591633
申请日：2005-03-02
申请人： Karl-Hermann Schmidt , Eberhard Straube , Stefan Russwurm , Hans-Peter Deigner , Svea Sachse , Marc Lehmann
发明人： Karl-Hermann Schmidt , Eberhard Straube , Stefan Russwurm , Hans-Peter Deigner , Svea Sachse , Marc Lehmann
CPC分类号： C12N15/1006 , C12N15/1003
摘要： The invention relates to a method for separating and/or enriching prokaryotic DNA, comprising the following steps: a) contacting of at least one prokaryotic DNA that is in solution with a protein that bonds specifically to prokaryotic DNA, the protein being 25%-35% homologous with the wild-type CGPB protein, thus forming a protein-DNA complex; and b) separation of the complex. The invention also relates to a kit for carrying out said method.
摘要翻译： 本发明涉及分离和/或富集原核DNA的方法，包括以下步骤：a）将至少一种在溶液中的原核DNA与特异性结合于原核DNA的蛋白质接触，所述蛋白质为25％-35 与野生型CGPB蛋白质同源，从而形成蛋白质-DNA复合物; 和b）复合物的分离。 本发明还涉及一种用于执行所述方法的套件。
-
6.发明申请Method for Enriching and/or Separating Prokaryotic Dna Using a Protein that Specifically Bonds to Unmethylated Dna Containing Cpg-Motives 失效使用特异性结合含有Cpg动机的非甲基化Dna的蛋白质来丰富和/或分离原核Dna的方法公开(公告)号：US20080003568A1
公开(公告)日：2008-01-03
申请号：US10591633
申请日：2005-03-02
申请人： Karl-Hermann Schmidt , Eberhard Straube , Stefan Russwurm , Hans-Peter Deigner , Svea Sachse , Marc Lehmann
发明人： Karl-Hermann Schmidt , Eberhard Straube , Stefan Russwurm , Hans-Peter Deigner , Svea Sachse , Marc Lehmann
CPC分类号： C12N15/1006 , C12N15/1003
摘要： The invention relates to a method for separating and/or enriching prokaryotic DNA, comprising the following steps: a) contacting of at least one prokaryotic DNA that is in solution with a protein that bonds specifically to prokaryotic DNA, said protein being 25%-35% homologous with the wild-type CGPB protein, thus forming a protein-DNA complex; and b) separation of the complex. The invention also relates to a kit for carrying out said method.
摘要翻译： 本发明涉及分离和/或富集原核DNA的方法，包括以下步骤：a）将至少一种在溶液中的原核DNA与特异性结合于原核DNA的蛋白质接触，所述蛋白质为25％-35 与野生型CGPB蛋白质同源，从而形成蛋白质-DNA复合物; 和b）复合物的分离。 本发明还涉及一种用于执行所述方法的套件。
-
公开(公告)号：US07301043B2
公开(公告)日：2007-11-27
申请号：US10497672
申请日：2002-10-23
IPC分类号： C07F9/02
CPC分类号： C12Q1/44 , C07F9/10 , G01N2333/918
摘要： Compounds for determining the activity of phospholipase A2, are described herein, and include embodiments having formula (1) wherein L1 is derived from an ether (R1—OR2)m, wherein R1 and R2 are independently selected and are derived from a hydrocarbon having 1 to 12 carbon atoms, with m being an integer from 1 to 4, or from a hydrocarbon R having 1 to 20 carbon atoms; F is unsubstituted or substituted pyrene as a flouraphore; Q is a quencher, and L2 is C(O)-L1 or C(O)-L1-NH, wherein L1 is as defined above. These compounds may be used to determine the activity of phospholipase A2, in particular PAF-AH.
摘要翻译： 用于确定磷脂酶A 2活性的化合物在本文中描述，并且包括具有式（1）的实施方案，其中L 1来自醚（R 1） 其中R 1和R 2独立地被选择并衍生自其中R 1，R 2和R 2， 由具有1至12个碳原子的烃，m为1至4的整数，或具有1至20个碳原子的烃R; F是未取代的或取代的芘作为透明物; Q是猝灭剂，L 2是C（O）-L 1或C（O）-L 1 -NH，其中L 1 如上所定义。 这些化合物可用于测定磷脂酶A 2活性，特别是PAF-AH。
-
公开(公告)号：US20080286763A1
公开(公告)日：2008-11-20
申请号：US10591371
申请日：2004-12-15
CPC分类号： C12Q1/6876 , B82Y5/00 , B82Y10/00 , C12Q1/6837 , C12Q2600/158 , Y10T436/143333
摘要： The invention relates to a method for the in vitro discrimination between systemic inflammatory non-infectious conditions and systemic inflammatory infectious conditions. The method comprises the following steps: a) sample RNA is isolated from a biological sample; b) the sample RNA and/or at least one DNA which represents a gene activity that is specific for distinguishing between SIRS and sepsis and/or a specific gene or gene fragment, is marked with a detectable marker; c) the sample RNA is brought in contact with the DNA in hybridization conditions; d) control RNA is brought in contact with at least one DNA in hybridization conditions, the DNA representing a gene or gene fragment that is specific for distinguishing between SIRS and sepsis; e) the marking signals of the hybridized sample RNA and control RNA are quantitatively recorded; and f) the quantitative data of the marking signals is compared in order to make a statement as to whether genes or gene fragments that are specific for distinguishing between SIRS and sepsis are expressed more prominently or less prominently in the sample than in the control RNA.
摘要翻译： 本发明涉及一种体内鉴别全身炎症非感染状况与全身性炎症感染状况的方法。 该方法包括以下步骤：a）从生物样品中分离样品RNA; b）用可检测标记标记样品RNA和/或代表特异于区分SIRS和脓毒症和/或特定基因或基因片段的基因活性的至少一种DNA; c）样品RNA在杂交条件下与DNA接触; d）控制RNA在杂交条件下与至少一种DNA接触，DNA代表特异于区分SIRS和败血症的基因或基因片段; e）定量记录杂交样品RNA和对照RNA的标记信号; 和f）比较标记信号的定量数据，以便作出关于在样品中比在对照RNA中更明显或更不显着地区分SIRS和败血症特异性的基因或基因片段的表述。
-
公开(公告)号：US20050064532A1
公开(公告)日：2005-03-24
申请号：US10497672
申请日：2002-10-23
CPC分类号： C12Q1/44 , C07F9/10 , G01N2333/918
摘要： What is described are compounds of formula (1) wherein L1 is derived from an ether (R1—OR2)m, wherein R1 and R2 are independently selected and are derived from a hydrocarbon having 1 to 12 carbon atoms, with m being an integer from 1 to 4, or from a hydrocarbon R having 1 to 20 carbon atoms; F is unsubstituted or substituted pyrene as a fluorophore; Q is a quencher, and L2 is C(O)-L1 or C(O)-L1-NH, wherein L1 is as defined above. These compounds may be used to determine the activity of phospholipase A2, in particular PAF-AH.
摘要翻译： 描述的是式（1）的化合物，其中L 1衍生自醚（R 1 -OR 2）m，其中R 1和R 2独立地选自并且衍生自具有 1至12个碳原子，m为1至4的整数，或具有1至20个碳原子的烃R; F是未取代的或取代的芘作为荧光团; Q是猝灭剂，L2是C（O）-L1或C（O）-L1-NH，其中L1如上所定义。 这些化合物可用于测定磷脂酶A2，特别是PAF-AH的活性。
-
公开(公告)号：US20100086909A1
公开(公告)日：2010-04-08
申请号：US11547007
申请日：2005-01-14
CPC分类号： C12Q1/6876 , C12Q2600/118 , C12Q2600/158
摘要： The invention relates to the use of gene expression profiles, obtained in vitro from a patient sample, for the generation of criteria for the prediction of an individual course of disease in sepsis. The invention is further of use for determining the probability of survival in sepsis, the assessment of the course of disease in sepsis during treatment and for the classification of sepsis patients.
摘要翻译： 本发明涉及使用从患者样品体外获得的基因表达谱用于产生用于预测脓毒病中个体病程的标准。 本发明进一步用于确定败血症中存活的可能性，评估治疗期间败血症的疾病过程和败血症患者的分类。
-
-
-
-
-
-
-
-
-
搜索结果
23 条记录 (耗时 0.027 秒)
